Health24.com Of those patients, almost 60 percent were initially treated with metformin, and about one-quarter began treatment with a sulfonylurea, such as Glucotrol, according to the study. Just 6 percent were started with a thiazolidinedione , such as Actos, and ... and more »
Defiance Crescent News (subscription) In 2013, the Cleveland Clinic published research with similar outcomes using another type of diabetes drug , thiazolidinedione . Several study trials are examining the use of Metformin and healthy lifestyle changes as a complement to chemotherapy for ...
News-Medical.net The study found that patients who started treatment with a sulfonylurea (SFU), a dipeptidyl peptidase-4 (DPP-4) inhibitor, and a thiazolidinedione (TZ...
PR Newswire (press release) Actos has been a prescribed diabetes medication since 1999 and is type of thiazolidinedione (TZD) that has been connected to a variety of side effects such as bladder cancer, cardiovascular problems, liver issues and fractures. Often individuals and ... and more »
Everyday Health Sulfonylurea stimulates the release of insulin from the pancreas. While the medication does work quickly, it may cause severe low blood sugar, weight gain, nausea, and skin rashes. TZD, or Thiazolidinedione , helps improve the body's sensitivity to ... and more »
American Pharmacists Association, pharmacist.com ... as dulaglutide include the low risk of hypoglycemia, especially when administered with metformin or a thiazolidinedione ; the weight-loss effects of these agents; and potential adherence benefits associated with drugs that only require once-weekly ...
WebMD The researchers found that around 40 percent of people taking a sulfonylurea, a thiazolidinedione , or a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor) added ...
The Pharmaceutical Journal Only 24.5% of patients on metformin needed a second glucose-lowering medication , compared with 37.1% given a sulfonylurea, 39.6% treated with a thiazolidinedione and 36.2% with a DPP-4 inhibitor. For the latter three drugs , metformin was the most ...
Diabetes In Control While 24.5% patients on metformin required an add-on oral medication , 37.1% of patients on sulfonylurea, 39.6% of patients on thiazolidinedione , and 36.2% patients on DPP-4 inhibitor required an add-on oral medication . Moreover, 5.1% of patients on ...
